Please ensure Javascript is enabled for purposes of website accessibility

Faulty COVID-19 Test Kits Tilt Scales in Coronavirus's Favor

By Cory Renauer - Updated Mar 3, 2020 at 3:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Flawed coronavirus test kits from the Centers for Disease Control severely limited the number of U.S. patients screened in January and February.

The U.S. government's response to the rapidly escalating coronavirus outbreak is receiving a strong dose of criticism. Instead of quickly testing every individual known to have been exposed to SARS-CoV-2, the coronavirus that causes COVID-19, just 3,600 were tested during January and February.

A world-class bottleneck

The first misstep along the path to what could become an uncontained outbreak in this country belonged to the Centers for Disease Control. Instead of using testing kits already provided by the World Health Organization, the CDC decided to create its own. Unfortunately, there have been problems with the test kits sent out by the CDC that rendered most of them useless. 

Coronavirus blood vial

Image source: Getty Images.

The CDC didn't begin sending testing kits to hospitals until Feb. 4, which means thousands of blood samples were sent to one of just 12 approved testing facilities. Tightening the bottleneck even further, all results needed to be certified by the CDC's central lab in Atlanta due to reagents that failed initial quality checks.

In the EU, a U.S. company called Co-Diagnostics (CODX -1.64%) has already launched a COVID-19 test available in every member state. Meanwhile, in the U.S., hospitals weren't able to use tests they already had access to until the beginning of March.

Sleepless in New York and Seattle 

It wasn't until Tuesday that the public learned that a person who died in a Seattle hospital last week had a COVID-19 infection when they were admitted to that facility on Feb. 24. Several other coronavirus cases have been diagnosed among residents of the nursing home where that patient lived.

Across the country, a second patient in New York City has tested positive. While the first COVID-19 positive patient in NYC got sick after returning from Iran, the second confirmed case is from a man who recently traveled to Miami. 

Get ready for a lot more confirmed COVID-19 diagnoses as the testing backlog is cleared. As of midday on March 3, just 12 people in NYC had been tested. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$5.40 (-1.64%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.